Great Point Partners LLC Vaxcyte, Inc. Transaction History

Great Point Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $7.76 Million - $10.9 Million	-171,211 Reduced 32.23%	360,000 $22.6 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $2.67 Million - $3.08 Million	-58,000 Reduced 9.84%	531,211 $27.1 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $2.43 Million - $3.78 Million	-70,000 Reduced 10.62%	589,211 $29.4 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $5.11 Million - $6.65 Million	-140,789 Reduced 17.6%	659,211 $24.7 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $4.12 Million - $9.59 Million	200,000 Added 33.33%	800,000 $38.4 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $8.35 Million - $11 Million	-385,153 Reduced 39.1%	600,000 $14.4 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $1.77 Million - $2.66 Million	100,000 Added 11.3%	985,153 $21.4 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $6.72 Million - $10.2 Million	385,153 Added 77.03%	885,153 $21.4 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $7.77 Million - $10.6 Million	401,939 Added 409.89%	500,000 $11.9 Million
Q3 2021 Nov 15, 2021	BUY	$20.26 - $26.97 $1.99 Million - $2.64 Million	98,061 New	98,061 $2.49 Million

353

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.13B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.